featured
Nivolumab With or Without Ipilimumab for Recurrent or Metastatic Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Lancet Oncol 2024 May 01;25(5)588-602, A Oaknin, K Moore, T Meyer, J López-Picazo González, LA Devriese, A Amin, CD Lao, V Boni, WH Sharfman, JC Park, M Tahara, SL Topalian, M Magallanes, A Molina Alavez, TA Khan, C Copigneaux, M Lee, C Garnett-Benson, X Wang, RW NaumannFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.